Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in FLT3-ITD Acute Myeloid Leukemia.

Pierre-Yves Dumas Arnaud Villacreces Amélie Valérie Guitart Ali El-HabhabLayal MassaraOlivier MansierAudrey BidetDelphine MartineauSolene FernandezThibaut LeguayArnaud PigneuxIsabelle VigonJean-Max PasquetVanessa Desplat

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Overall, these findings suggest that gilteritinib as a single agent, compared with quizartinib, is more likely to reach leukemic cells in their protective microenvironment, particularly AML clones highly dependent on FLT3-ITD signaling.

Keyphrases

acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
induced apoptosis
cell cycle arrest
stem cells
bone marrow
tyrosine kinase
oxidative stress
cell proliferation